Christopher Pierce net worth and biography

Christopher Pierce Biography and Net Worth

Christopher Pierce, M.B.A. has served as our Executive Vice President and Chief of Business Operations since July 2020. Mr. Pierce previously served as Principal and Founder of Scout Advisers, LLC, a life sciences consultancy, from August 2019 to July 2020. Prior to that, Mr. Pierce served as Vice President, Head of Commercial from January 2018 to May 2019, and as Executive Director, Commercial from April 2017 to December 2017, at Loxo Oncology, Inc., a biopharmaceutical company. Mr. Pierce held several roles at Pfizer Inc., a biopharmaceutical company, including as Senior Director/Global Commercial Lead, Hematologic Malignancies Portfolio from July 2016 to March 2017, and as Portfolio Lead, US Marketing from March 2015 to July 2016. Mr. Pierce received an A.B. degree in Biochemical Sciences from Harvard College, and an M.B.A. from the Harvard Business School.

What is Christopher Pierce's net worth?: The estimated net worth of Christopher Pierce is at least $16,205.75 as of September 2nd, 2021. Mr. Pierce owns 20,750 shares of Prelude Therapeutics stock worth more than $16,206 as of May 11th. This net worth approximation does not reflect any other assets that Mr. Pierce may own. Learn More about Christopher Pierce's net worth.
How do I contact Christopher Pierce?: The corporate mailing address for Mr. Pierce and other Prelude Therapeutics executives is , , . Prelude Therapeutics can also be reached via phone at 302-467-1280 and via email at prelude@argotpartners.com. Learn More on Christopher Pierce's contact information.
Has Christopher Pierce been buying or selling shares of Prelude Therapeutics?: Christopher Pierce has not been actively trading shares of Prelude Therapeutics during the last ninety days. Most recently, Christopher Pierce sold 17,000 shares of the business's stock in a transaction on Thursday, September 2nd. The shares were sold at an average price of $41.68, for a transaction totalling $708,560.00. Following the completion of the sale, the executive vice president now directly owns 20,750 shares of the company's stock, valued at $864,860. Learn More on Christopher Pierce's trading history.
Who are Prelude Therapeutics' active insiders?: Prelude Therapeutics' insider roster includes Andrew Combs (EVP), David Mauro (Insider), Deborah Morosini (EVP), Christopher Pierce (EVP), Brian Piper (CFO), and Peggy Scherle (Insider). Learn More on Prelude Therapeutics' active insiders.
Are insiders buying or selling shares of Prelude Therapeutics?: In the last year, Prelude Therapeutics insiders bought shares 8 times. They purchased a total of 1,020,575 shares worth more than $781,961.25. The most recent insider tranaction occured on March, 25th when insider Andrew Combs bought 100,000 shares worth more than $69,000.00. Insiders at Prelude Therapeutics own 62.8% of the company. Learn More about insider trades at Prelude Therapeutics.
Information on this page was last updated on 3/25/2025.

Christopher Pierce Insider Trading History at Prelude Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/2/2021	Sell	17,000	$41.68	$708,560.00	20,750
4/29/2021	Sell	3,295	$40.29	$132,755.55	3,667
4/7/2021	Sell	828	$40.08	$33,186.24	4,578

Christopher Pierce Buying and Selling Activity at Prelude Therapeutics

Prelude Therapeutics Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Today's Range

Now: $0.78

$0.78

$0.87

50 Day Range

MA: $0.76

$0.61

$0.96

2 Week Range

Now: $0.78

$0.61

$6.80

Volume

76,739 shs

Average Volume

269,885 shs

Market Capitalization

$34.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3